1Massachusetts General Hospital, Boston, MA, United States; 2Charit Universittsmedizin, Berlin, Germany; 3Harvard School of Public Health, Boston, MA, United States
Despite lung cancer being the primary cause of cancer related death in both men and women in the United States, there is no early screening tool available to the general public. Due to the high costs and the radiation exposure of CT or PET, these technologies are not feasible as screening tools. Clinicians desperately need a new diagnostic tool to provide biochemical information that is essential for making early diagnoses and subsequent treatment decisions. In this study we are assessing the matched tissue and sera metabolomic profiles of lung cancer patients to discover serum metabolic markers for lung cancer.